(NASDAQ: ITOS) Iteos Therapeutics's forecast annual revenue growth rate of 120.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Iteos Therapeutics's revenue in 2024 is $12,595,000.On average, 2 Wall Street analysts forecast ITOS's revenue for 2024 to be $2,017,968,275, with the lowest ITOS revenue forecast at $451,623,451, and the highest ITOS revenue forecast at $3,584,313,100. On average, 2 Wall Street analysts forecast ITOS's revenue for 2025 to be $727,794,775, with the lowest ITOS revenue forecast at $114,698,019, and the highest ITOS revenue forecast at $1,340,891,531.
In 2026, ITOS is forecast to generate $5,547,548,914 in revenue, with the lowest revenue forecast at $920,093,173 and the highest revenue forecast at $12,322,868,438.